Trial Profile

A first-in-human safety and exploratory biomarker study with of OV350

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2024 According to an Ovid Therapeutics media release, company expects to submit a regulatory application for a Phase 1 trial of OV350 before year end 2024, and to initiate the first-in-human study for this class of molecule in Q1 2025.
13 Aug 2024 According to an Ovid Therapeutics media release, company intends to submit an application to study an IV formulation of OV350 in healthy human volunteers in H2 2024.
17 Jun 2024 According to an Ovid Therapeutics media release,First-in-human data is expected in H1 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com